Phillips Medisize Acquires Chippenham Facility to Expand Global Inhalation Center of Excellence

Contributed by: Business Wire

Logo

Tags

Biotechnology

Pharmaceutical

Health

Medical Devices

Chippenham Facility

More Like This

Phillips Medisize Expands Its Inhalation Drug Delivery Capabilities

Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

Phillips Medisize Announces Scientific Presentations and Engagements at Respiratory Drug Delivery Conference, Highlighting Its Expanded Inhalation Drug Delivery Capabilities

Vectura Fertin Pharma, Inc., a Subsidiary of Philip Morris International, Announces Agreement for Sale of Vectura Group to Molex

PR Newswire associated0

Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan

PCI Pharma Services is investing more than $365 million in infrastructure supporting the clinical and commercial-scale final assembly and packaging of drug-device combination products utilizing advanced drug delivery systems, with an emphasis on injectable formats. (Photo: Business Wire)

PCI Pharma Services Invests Over $365 Million in EU, US Facilities for Clinical and Commercial Supply of Advanced Drug Delivery and Drug-Device Combination Products

PR Newswire associated0

Piramal Pharma Ltd. Continues to Invest In USA; $90M in Expansions of Two US Sites

PCI Pharma Services announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities.

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities